Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.
By S. Frustaci, F. Gherlinzoni, A. De Paoli, M. Bonetti, A. Azzarelli, A. Comandone, P. Olmi, A. Buonadonna, G. Pignatti, E. Barbieri and 4 more. Journal of Clinical Oncology, 2001
679 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/3a750758f2ea3c237fdd45a49f5e0869eadf7d26
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, result): “Study results are conflicting, in the presence of negative results from the largest studies, though data are available from smaller studies suggesting that it might improve, or at least delay, distant and local recurrence in high-risk patients [13, 14].”
- Soft Tissue Sarcomas (2001, background): “001).(69) On the basis of these results, the authors concluded that the extent of pathologic necrosis may be considered a surrogate endpoint for survival outcomes in patients with soft tissue sarcomas.”
- Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, result): “Study results are conflicting, in the presence of negative results from the largest studies, though data are available from smaller studies suggesting that adjuvant ChT might improve, or at least delay, distant and local recurrence in high-risk patients [18, 19].”
- A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma (2008, background): “In contrast, all 4 additional studies in the current metaanalysis included an arm with ifosfamide in addition to doxorubicin.(18-21) In a subgroup analysis for overall survival, we found that data pooled from all studies with only doxorubicin-based protocols did not show a statistically significant ”